The findings reported by Zhang et al. were recently confirmed by Shepherd and colleagues who evaluated the prognostic and predictive roles of TP53/KRAS and TP53/EGFR co-mutations in 3,533 patients from the LACE (Lung Adjuvant Cisplatin Evaluation) database of randomized trials of adjuvant chemotherapy versus observation in early stage resected NSCLC [19]. The gene discussed is TP53; the disease is non-small cell lung carcinoma.